Alec Hogg: Ivermectin gets big US research thumbs up

A new addition to your Premium newsletter today as we kick off our licensing agreement with the FT. The piece republished below offers an insight into what Western Europe is reading today about the Zuma conviction. On the same tack, you may also enjoy my interview yesterday with Accountability Now's Adv Paul Hoffman.

For clarity – our partnership with the FT entitles BizNews to republish a certain number of its articles. Unfortunately, it does NOT entitle our Premium members to access FT.com as part of their BizNews subscription. That applies only to our partnership with the Wall Street Journal. If you have not yet triggered your WSJ sub (retails at $26 a month) there's guidance on how to do so at the bottom of this mail.

* Meta-analysis by the American Journal of Therapeutics of 60 studies has given a big thumbs up to Ivermectin as a shield against COVID. Rubin van Niekerk's in-depth report on the study is on BizNews.com this morning. Also, click here for the MedicalBrief report on the same study. Rounding off a forgettable news day for SA's anti-Ivermectin Health Professionals Council is MedicalBrief's publication of a High Court judgement which it describes as "a judicial tongue lashing" for the HPCSA.

___STEADY_PAYWALL___